Document is current
Any future updates will be listed below
-
Authors
Pearl, Rebecca L.
Li, Yulin
Groshon, Laurie C.
Hernandez, Marian
Saunders, Danielle
Sheynblyum, Miriam
Driscoll, Kimberly A.
Gelfand, Joel M.
Manavalan, Preeti
Montanez-Wiscovich, Marjorie
Pereira, Deidre B.
Puhl, Rebecca M.
Wadden, Thomas A.
Waxenberg, Lori B.
Westen, Sarah C.
Lou, Xiang-Yang
- License Information
-
More Information
Article History
Received: 1 May 2024
Accepted: 26 September 2024
First Online: 8 October 2024
Declarations
:
: This study was approved by the University of Florida Institutional Review Board (Protocol IRB202201862).
: N/A.
: Dr. Gelfand served as a consultant for Abbvie, Artax (DSMB), BMS, Boehringer Ingelheim, Celldex (DSMB), FIDE (which is sponsored by multiple pharmaceutical companies) GSK, Inmagene (DSMB), Lilly, Leo, Moonlake (DSMB), Janssen Biologics, Novartis Corp, UCB (DSMB), Neuroderm (DSMB), and Veolia North America receiving honoraria; receives research grants (to the Trustees of the University of Pennsylvania) from Amgen, BMS, and Pfizer Inc.; and received payment for continuing medical education work related to psoriasis that was supported indirectly pharmaceutical sponsors. Dr. Gelfand is a co-patent holder of resiquimod for treatment of cutaneous T cell lymphoma. Dr Gelfand is a Deputy Editor for the Journal of Investigative Dermatology receiving honoraria from the Society for Investigative Dermatology, is Chief Medical Editor for Healio Dermatology (receiving honoraria), and is a member of the Board of Directors for the International Psoriasis Council and the Medical Dermatology Society, receiving no honoraria. The other authors declare that they have no competing interests.
